UPC stock surges 288% after hours on unspecified drivers behind the rally. 288% after-hours surge signals major short-term shift in investor sentiment with potential to alter near-term trajectory.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 5.29 | 29.50 | 33.59 | 29.05 |
| Receivables | 13.00 | 18.57 | 15.29 | 22.14 |
| Inventory | 3.34 | 1.74 | 2.19 | 1.98 |
| Other | 3.61 | 0.98 | 2.49 | 2.00 |
| 25.27 | 51.64 | 53.60 | 55.21 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 4.59 | 4.91 | 1.67 | 3.75 |
| ST’ Debt | 5.48 | 5.86 | 9.26 | 7.38 |
| Other | — | — | 0.04 | 0.04 |
| 13.75 | 20.31 | 13.17 | 13.65 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
17.86
|
| ’24 | — | — | — | — |
23.02
|
| ’23 | 18.47 | — | — | — |
32.31
|
| ’22 | 24.20 | — | 15.94 | — |
40.14
|
| ’21 | 24.29 | — | 23.69 | — |
47.98
|
| ’20 | — | — | — | — |
30.70
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.30) | — | — | — |
—
|
| ’25 | 2.56 | — | (5.05) | — |
(5.05)
|
| ’24 | (2.43) | — | (9.51) | — |
(9.51)
|
| ’23 | 4.80 | — | 1.12 | — |
1.12
|
| ’22 | 6.12 | — | (1.31) | — |
(1.31)
|
| ’21 | 1.06 | — | (2.06) | — |
(2.06)
|
| ’20 | — | — | 6.12 | — |
6.12
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.62) | — | — | — |
—
|
| ’25 | 2.43 | — | (5.31) | — |
(5.39)
|
| ’24 | (2.50) | — | (9.75) | — |
(9.87)
|
| ’23 | 4.80 | — | 1.08 | — |
1.07
|
| ’22 | 6.06 | — | (1.41) | — |
(1.41)
|
| ’21 | 1.06 | — | (13.13) | — |
(13.13)
|
| ’20 | — | — | 6.06 | — |
6.06
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
(8.06)
|
| ’24 | — | — | — | — |
(626.96)
|
| ’23 | (0.20) | — | — | — |
(1.02k)
|
| ’22 | 0.48 | — | (2.89) | — |
(1.44k)
|
| ’21 | 1.97 | — | 1.15 | — |
2.16k
|
| ’20 | — | — | — | — |
2.06
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 1,800.00 | 450.00 | 24.12 | 2.51 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 6,768.00 | 7,488.00 | 2,592.00 | 27.16 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 224 | 225 | 225 | 216 | — | — | — |
Employees
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.18 | 0.14 | 0.10 | 0.08 | — | — | — |
Revenue/Emp
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 40.14 | 32.31 | 23.02 | 17.86 | — | — | — |
Revenue
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 54.53% | 31.93% | 26.37% | 35.28% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.98) | (4.33) | (8.12) | (3.67) | — | — | — |
EBT
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (19.89%) | (13.39%) | (35.27%) | (20.56%) | — | — | — |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (8.74) | (6.58) | (8.73) | (3.67) | — | — | — |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.53 | 0.51 | 0.49 | 0.52 | — | — | — |
Depreciation
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6,690.53 | 5,384.78 | 1,656.44 | 39.17 | — | — | — |
Revenue/Sh
|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | (1,438.99) | (1,019.49) | (626.96) | (8.06) | — | — | — |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (218.72) | 186.13 | (683.94) | (11.08) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (15.53) | (7.37) | (25.99) | (0.75) | — | — | — |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (234.25) | 178.77 | (709.93) | (11.83) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7,740.38 | 4,661.70 | 3,273.59 | 123.12 | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.01 | 0.01 | 0.01 | 0.46 | — | — | — |
Shares
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,864.79 | 0.00 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 83.67 | 34.09 | 6.45 | 0.19 | — | — | — |
PS Ratio
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 158.76 | 100.46 | 11.66 | 0.27 | — | — | — |
PB Ratio
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 83.50 | 34.09 | 6.19 | (0.09) | — | — | — |
EV/Sales
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | (985.58) | 266.42 | (79.88) | 0.47 | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.31) | 1.12 | (9.51) | (5.05) | — | — | — |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.09) | (0.04) | (0.36) | (0.34) | — | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.41) | 1.07 | (9.87) | (5.39) | — | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.41 | 11.52 | 31.32 | 40.43 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.94 | 5.48 | 7.99 | 9.26 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.92) | 0.20 | (21.50) | (24.34) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 46.44 | 27.97 | 45.50 | 56.13 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.47%) | (13.00%) | (15.91%) | (5.35%) | — | — | — |
ROA
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.75%) | (8.80%) | (20.89%) | (5.73%) | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (16.58%) | (17.69%) | (23.76%) | (7.23%) | — | — | — |
ROE
|
Universe Pharmaceuticals INC (UPC), a traditional Chinese medicine player, has plummeted over 90-99% from its 2021 peaks, trading at deeply discounted valuations like a 0.19x price-to-sales ratio and 0.28x price-to-book amid revenue collapse and mounting losses. Revenue surged 56% to $47.9 million in 2021, driven by pandemic demand, but has since eroded sharply—down 29% to $23 million in 2024—with analysts forecasting a further 22% drop to $17.9 million in 2025. Profitability flipped from $11.3 million net income in 2021 to $8.7 million losses in 2024, with gross margins cratering to 26.4% and efficiency metrics like ROE turning negative at -23.8%.
Despite operational woes, UPC’s balance sheet remains a fortress: net cash-rich with $24.3 million in net cash projected for 2025, ample working capital, and shareholders’ equity rebounding to $45.5 million. However, massive share dilution—shares outstanding up over 10,000% to 455,900—has ravaged per-share metrics, explaining the stock’s derating from hype-fueled highs near $43,000 to recent lows around $24. Broader headwinds from U.S.-China tensions, China’s economic slowdown, and post-COVID shifts likely exacerbated the decline, with zero insider activity adding caution.
Analysts see short-term pain with narrowing losses but no growth beyond 2025, leaving UPC as a high-risk speculative bet. Trading at a steep discount to book value, it could reward value hunters if TCM demand rebounds via global wellness trends or export easing, but dilution risks and absent Wall Street coverage demand caution—potentially a beaten-down gem or persistent trap.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.